KR100866720B1 - 항치매 약물의 안정화 방법 - Google Patents
항치매 약물의 안정화 방법 Download PDFInfo
- Publication number
- KR100866720B1 KR100866720B1 KR1020077014535A KR20077014535A KR100866720B1 KR 100866720 B1 KR100866720 B1 KR 100866720B1 KR 1020077014535 A KR1020077014535 A KR 1020077014535A KR 20077014535 A KR20077014535 A KR 20077014535A KR 100866720 B1 KR100866720 B1 KR 100866720B1
- Authority
- KR
- South Korea
- Prior art keywords
- acid
- molecular weight
- high molecular
- group
- donepezil
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Abstract
Description
Claims (31)
- 도네페질 또는 그의 제약학적으로 허용되는 염, 및 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질을 포함하는 제약 조성물에, 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 첨가하는 것을 포함하는, 도네페질 또는 그의 제약학적으로 허용되는 염의 안정화 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 제1항에 있어서, 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두를 첨가하는 것을 추가로 포함하는 안정화 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 이용하여, 도네페질 또는 그의 제약학적으로 허용되는 염과 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질의 접촉에 의해 생성되는 도네페질 또는 그의 제약학적으로 허용되는 염의 분해물을 억제하는 방법.
- 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두와, 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 이용하여, 도네페질 또는 그의 제약학적으로 허용되는 염과 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질의 접촉에 의해 생성되는 도네페질 또는 그의 제약학적으로 허용되는 염의 분해물을 억제하는 방법.
- 도네페질 또는 그의 제약학적으로 허용되는 염, 및 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질을 포함하며, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위해 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 추가로 포함하는 제약 조성물.
- 제18항에 있어서, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위한 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두를 추가로 포함하는 제약 조성물.
- 제18항에 있어서,도네페질 또는 그의 제약학적으로 허용되는 염,에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질, 및도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위한 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질의 혼합물을 포함하는 매트릭스를 포함하는 제약 조성물.
- 제20항에 있어서, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위한 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두가 매트릭스 내에 혼합되어 있는 제약 조성물.
- 제18항에 있어서,도네페질 또는 그의 제약학적으로 허용되는 염을 포함하는 코어, 및코어를 피복하는 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질을 포함하는 코팅층을 포함하며, 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질은 코어 및 코팅층 중 어느 하나 또는 이들 모두 내에 혼합되어 있는 제약 조성물.
- 제22항에 있어서, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위한 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두가 코어 및 코팅층 중 어느 하나 또는 이들 모두 내에 추가로 혼합되어 있는 제약 조성물.
- 제18항 내지 제23항 중 어느 한 항에 있어서, 서방성 제제인 제약 조성물.
- 삭제
- 도네페질 또는 그의 제약학적으로 허용되는 염,에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질, 및메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 포함하는 매트릭스형 서방성 제제.
- 제26항에 있어서, 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두를 추가로 포함하는 매트릭스형 서방성 제제.
- 도네페질 또는 그의 제약학적으로 허용되는 염과, 에틸셀룰로오스, 아크릴산에틸-메타크릴산메틸 공중합체 및 폴리에틸렌옥시드로 이루어지는 군으로부터 선택되는 고분자량 염기성 물질을 혼합하는 단계, 및혼합물을 과립화하는 단계를 포함하며, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위해 메타크릴산-아크릴산에틸 공중합체, 메타크릴산-메타크릴산메틸 공중합체, 히드록시프로필메틸셀룰로오스 프탈레이트 및 히드록시프로필메틸셀룰로오스 아세테이트 숙시네이트로 이루어지는 군으로부터 선택되는 고분자량 산성 물질을 혼합 단계 및 과립화 단계 중 어느 하나 또는 이들 모두의 단계 중에, 상기 도네페질 또는 그의 제약학적으로 허용되는 염과 상기 고분자량 염기성 물질의 혼합물에 첨가하는, 제약 조성물의 제조 방법.
- 제28항에 있어서, 고분자량 산성 물질을 분말로서 첨가하는 제조 방법.
- 제28항 또는 제29항에 있어서, 도네페질 또는 그의 제약학적으로 허용되는 염을 안정화시키기 위해 숙신산, 타르타르산, 시트르산, 푸마르산, 말레산, 말산, 아스파르트산, 글루탐산, 글루탐산 히드로클로라이드, 염산 및 인산으로 이루어지는 군으로부터 선택되는 저분자량 산성 물질, 및아스코르브산, 황 함유 아미노산, 히드로퀴논 유도체 및 토코페롤로 이루어지는 군으로부터 선택되는 항산화제중 어느 하나 또는 이들 모두를 혼합 단계 및 과립화 단계 중 어느 하나 또는 이들 모두의 단계 중에, 상기 도네페질 또는 그의 제약학적으로 허용되는 염과 상기 고분자량 염기성 물질의 혼합물에 추가로 첨가하는 제조 방법.
- 제30항에 있어서, 저분자량 산성 물질 및 항산화제 중 어느 하나 또는 이들 모두를 용액 또는 현탁액으로서 첨가하는 제조 방법.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004376770 | 2004-12-27 | ||
JPJP-P-2004-00376770 | 2004-12-27 | ||
JP2005041492 | 2005-02-18 | ||
JPJP-P-2005-00041492 | 2005-02-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070086667A KR20070086667A (ko) | 2007-08-27 |
KR100866720B1 true KR100866720B1 (ko) | 2008-11-05 |
Family
ID=36615033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020077014535A KR100866720B1 (ko) | 2004-12-27 | 2005-12-27 | 항치매 약물의 안정화 방법 |
Country Status (14)
Country | Link |
---|---|
US (2) | US8481565B2 (ko) |
EP (1) | EP1830886B1 (ko) |
JP (2) | JP2008525313A (ko) |
KR (1) | KR100866720B1 (ko) |
AU (1) | AU2005320547B2 (ko) |
BR (1) | BRPI0518396A2 (ko) |
CA (1) | CA2592605C (ko) |
HK (1) | HK1112399A1 (ko) |
IL (1) | IL183650A (ko) |
MX (1) | MX2007007836A (ko) |
NO (1) | NO20073482L (ko) |
NZ (1) | NZ555693A (ko) |
RU (1) | RU2401125C2 (ko) |
WO (1) | WO2006070930A1 (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180036579A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
WO2020130287A1 (ko) | 2018-12-21 | 2020-06-25 | 동아에스티 주식회사 | 안정화된 도네페질 함유 경피 흡수제제 |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
US20070129402A1 (en) * | 2004-12-27 | 2007-06-07 | Eisai Research Institute | Sustained release formulations |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
CA2604617C (en) * | 2005-04-28 | 2014-06-17 | Eisai R&D Management Co., Ltd. | Composition containing anti-dementia drug |
US20080131490A1 (en) * | 2006-12-01 | 2008-06-05 | Akinori Hanatani | Stabilized donepezil-containing patch preparation |
RU2435570C2 (ru) * | 2006-12-01 | 2011-12-10 | Нитто Денко Корпорейшн | Композиция для чрескожного всасывания |
KR20090086565A (ko) * | 2006-12-01 | 2009-08-13 | 닛토덴코 가부시키가이샤 | 안정화된 도네페질 함유 접착 제제 |
RU2460521C2 (ru) * | 2006-12-01 | 2012-09-10 | Нитто Денко Корпорейшн | Способ подавления выцветания со временем адгезивной композиции, содержащей донепезил |
WO2008088039A1 (ja) * | 2007-01-19 | 2008-07-24 | Eisai R & D Management Co., Ltd. | ドネペジルを含有する安定化医薬組成物、その製造方法、及び安定化方法 |
GR20070100405A (el) * | 2007-06-26 | 2009-01-20 | Genepharm �.�. | Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων |
CA2718411C (en) | 2008-03-27 | 2016-02-16 | Chase Pharmaceuticals Corporation | Use and composition for treating dementia |
DE102009041839A1 (de) * | 2009-09-18 | 2011-03-24 | Dolorgiet Gmbh & Co. Kg | Donepezil-haltige Tabletten |
US8962014B2 (en) * | 2009-12-22 | 2015-02-24 | Acino Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
US10076502B2 (en) | 2009-12-22 | 2018-09-18 | Luye Pharma Ag | Transdermal therapeutic system for administering rivastigmine or derivatives thereof |
CN102711737A (zh) * | 2009-12-28 | 2012-10-03 | 尼普洛株式会社 | 品质提高的口服制剂 |
US20110218216A1 (en) * | 2010-01-29 | 2011-09-08 | Kumaravel Vivek | Extended release pharmaceutical composition of donepezil |
WO2011102504A1 (ja) | 2010-02-22 | 2011-08-25 | 第一三共株式会社 | 経口用徐放性固形製剤 |
EP2366378A1 (en) | 2010-03-01 | 2011-09-21 | Dexcel Pharma Technologies Ltd. | Sustained-release donepezil formulations |
JP2011213606A (ja) * | 2010-03-31 | 2011-10-27 | Sawai Pharmaceutical Co Ltd | ドネペジルを含有する固形製剤の製造方法 |
WO2012101653A2 (en) * | 2011-01-25 | 2012-08-02 | Cadila Healthcare Limited | Modified release pharmaceutical compositions memantine |
JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
EP2502620A1 (en) | 2011-03-24 | 2012-09-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising donepezil |
CN103417490B (zh) * | 2012-05-21 | 2015-06-17 | 成都康弘药业集团股份有限公司 | 一种含有盐酸多奈哌齐的颗粒剂及其制备方法 |
EP2961393B1 (en) | 2013-02-28 | 2020-10-28 | Lupin Limited | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
CA2902665C (en) | 2013-02-28 | 2021-03-02 | Lupin Limited | Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters |
KR101990951B1 (ko) * | 2015-04-27 | 2019-06-20 | 주식회사 네비팜 | 리바스티그민 함유 서방출 의약조성물 |
US10603292B2 (en) | 2017-05-31 | 2020-03-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11106353A (ja) * | 1997-10-01 | 1999-04-20 | Eisai Co Ltd | 光安定化組成物 |
Family Cites Families (226)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1894239A (en) | 1930-01-20 | 1933-01-10 | Ig Farbenindustrie Ag | Production of molybdenum and tungsten carbonyls |
US2327996A (en) | 1941-11-24 | 1943-08-31 | Thompson W Burnam | Process of dehydrating mineral oil emulsions |
HU187215B (en) | 1983-01-26 | 1985-11-28 | Egyt Gyogyszervegyeszeti Gyar | Method for producing pharmaceutical product of high actor content and prolonged effect |
IL72381A (en) | 1983-07-20 | 1988-03-31 | Sanofi Sa | Pharmaceutical composition based on valproic acid |
SE452177B (sv) | 1983-09-30 | 1987-11-16 | Nils Anders Lennart Wikdahl | Anordning for fraktionering av fibersuspensioner |
SE457505B (sv) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
DK62184D0 (da) | 1984-02-10 | 1984-02-10 | Benzon As Alfred | Diffusionsovertrukket polydepotpraeparat |
US4772475A (en) | 1985-03-08 | 1988-09-20 | Yamanouchi Pharmaceutical Co., Ltd. | Controlled-release multiple units pharmaceutical formulation |
NL8500724A (nl) | 1985-03-13 | 1986-10-01 | Univ Groningen | Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan. |
US4892742A (en) | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
IL81419A0 (en) | 1986-01-30 | 1987-08-31 | Syntex Inc | Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation |
US4940556A (en) | 1986-01-30 | 1990-07-10 | Syntex (U.S.A.) Inc. | Method of preparing long acting formulation |
IE63321B1 (en) | 1986-02-03 | 1995-04-05 | Elan Corp Plc | Drug delivery system |
US4832957A (en) | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
HU202753B (en) | 1986-06-21 | 1991-04-29 | Sandoz Ag | Process for producing retard pharmaceutical compositions containing cetotiphene |
US4970075A (en) | 1986-07-18 | 1990-11-13 | Euroceltique, S.A. | Controlled release bases for pharmaceuticals |
US4710384A (en) | 1986-07-28 | 1987-12-01 | Avner Rotman | Sustained release tablets made from microcapsules |
CA1308357C (en) | 1987-01-28 | 1992-10-06 | Tohru Chiba | Method for the preparation of a coated solid medicament |
US4851232A (en) | 1987-02-13 | 1989-07-25 | Alza Corporation | Drug delivery system with means for obtaining desirable in vivo release rate pattern |
US4968508A (en) | 1987-02-27 | 1990-11-06 | Eli Lilly And Company | Sustained release matrix |
US4894239A (en) | 1987-06-02 | 1990-01-16 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and production thereof |
EP0297866A3 (en) | 1987-07-01 | 1989-12-13 | The Boots Company PLC | Therapeutic agents |
US4792452A (en) | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4891223A (en) | 1987-09-03 | 1990-01-02 | Air Products And Chemicals, Inc. | Controlled release delivery coating formulation for bioactive substances |
JP2643222B2 (ja) | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
US5254347A (en) | 1988-03-31 | 1993-10-19 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation and method for producing the same |
JPH0768125B2 (ja) | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
DE3818207A1 (de) | 1988-05-28 | 1989-11-30 | Bosch Gmbh Robert | Reifendruck- und temperatursensor |
DE3827214A1 (de) | 1988-08-11 | 1990-02-15 | Roehm Gmbh | Retardierte arzneiform und verfahren zu ihrer herstellung |
JP2514078B2 (ja) | 1988-08-22 | 1996-07-10 | エスエス製薬株式会社 | 圧縮成型製剤 |
NZ231281A (en) | 1988-11-08 | 1991-01-29 | Takeda Chemical Industries Ltd | Sustained release pharmaceutical preparations comprising the active agent dispersed in a solid matrix of a fatty acid ester of a polyglycerol |
JP2893191B2 (ja) | 1988-11-08 | 1999-05-17 | 武田薬品工業株式会社 | 放出制御性マトリックス剤 |
US5202128A (en) | 1989-01-06 | 1993-04-13 | F. H. Faulding & Co. Limited | Sustained release pharmaceutical composition |
US5278474A (en) * | 1989-01-12 | 1994-01-11 | Tokyo Densoku Kabushiki Kaisha | Discharge tube |
ES2077023T3 (es) | 1989-03-10 | 1995-11-16 | Yamanouchi Pharma Co Ltd | Material de recubrimiento que controla la liberacion de un medicamento para formulaciones de actividad prolongada. |
NZ233403A (en) | 1989-04-28 | 1992-09-25 | Mcneil Ppc Inc | Simulated capsule-like medicament |
JP2572673B2 (ja) | 1990-07-25 | 1997-01-16 | エスエス製薬株式会社 | 徐放性錠剤 |
US5102668A (en) | 1990-10-05 | 1992-04-07 | Kingaform Technology, Inc. | Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH |
US5656295A (en) | 1991-11-27 | 1997-08-12 | Euro-Celtique, S.A. | Controlled release oxycodone compositions |
US5266331A (en) | 1991-11-27 | 1993-11-30 | Euroceltique, S.A. | Controlled release oxycodone compositions |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
US5681585A (en) | 1991-12-24 | 1997-10-28 | Euro-Celtique, S.A. | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer |
DE4225730C2 (de) | 1992-08-04 | 2003-04-30 | Merz Pharma Gmbh & Co Kgaa | Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung |
IT1258143B (it) | 1992-09-11 | 1996-02-20 | Alfa Wassermann Spa | Compresse a cessione programmata contenenti naproxen |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5455046A (en) | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
KR950007873A (ko) | 1993-09-20 | 1995-04-15 | 후꾸하라 요시하루 | 생리 활성 물질 지속 방출형의 의약 제제 |
US5500227A (en) | 1993-11-23 | 1996-03-19 | Euro-Celtique, S.A. | Immediate release tablet cores of insoluble drugs having sustained-release coating |
PL181214B1 (pl) | 1993-12-29 | 2001-06-29 | Merck Sharp & Dohme | Podstawione związki morfolinowe, sposób ich wytwarzania oraz zawierające je kompozycje farmaceutyczne |
AT403988B (de) | 1994-05-18 | 1998-07-27 | Lannacher Heilmittel | Festes orales retardpräparat |
US5698224A (en) | 1994-06-27 | 1997-12-16 | Alza Corporation | Tacrine therapy |
JPH0826977A (ja) * | 1994-07-19 | 1996-01-30 | Tanabe Seiyaku Co Ltd | 溶出制御型経口製剤 |
US20020006438A1 (en) | 1998-09-25 | 2002-01-17 | Benjamin Oshlack | Sustained release hydromorphone formulations exhibiting bimodal characteristics |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5871776A (en) | 1995-01-31 | 1999-02-16 | Mehta; Atul M. | Controlled-release nifedipine |
US6083532A (en) | 1995-03-01 | 2000-07-04 | Duramed Pharmaceuticals, Inc. | Sustained release formulation containing three different types of polymers and tablet formed therefrom |
FI98343C (fi) | 1995-03-21 | 1997-06-10 | Orion Yhtymae Oy | Peroraalinen formulaatio |
AUPN605795A0 (en) | 1995-10-19 | 1995-11-09 | F.H. Faulding & Co. Limited | Analgesic pharmaceutical composition |
US5840332A (en) | 1996-01-18 | 1998-11-24 | Perio Products Ltd. | Gastrointestinal drug delivery system |
IT1282650B1 (it) | 1996-02-19 | 1998-03-31 | Jagotec Ag | Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici |
US5773031A (en) | 1996-02-27 | 1998-06-30 | L. Perrigo Company | Acetaminophen sustained-release formulation |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
JPH09323926A (ja) * | 1996-03-15 | 1997-12-16 | Nikken Chem Co Ltd | バルプロ酸ナトリウムの徐放性錠剤 |
US6156340A (en) | 1996-03-29 | 2000-12-05 | Duquesne University Of The Holy Ghost | Orally administrable time release drug containing products |
US6096339A (en) | 1997-04-04 | 2000-08-01 | Alza Corporation | Dosage form, process of making and using same |
ATE302599T1 (de) * | 1996-05-24 | 2005-09-15 | Angiotech Pharm Inc | Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege |
TW513409B (en) | 1996-06-07 | 2002-12-11 | Eisai Co Ltd | Polymorphs of donepezil hydrochloride |
DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
US6310085B1 (en) | 1997-10-03 | 2001-10-30 | Clarencew Pty Ltd. | Method for the treatment of neurological or neuropsychiatric disorders |
AUPO274596A0 (en) | 1996-10-04 | 1996-10-31 | Armstrong, Stuart Maxwell | Method for the treatment of neurological or neuropsychiatric disorders |
IT1289160B1 (it) | 1997-01-08 | 1998-09-29 | Jagotec Ag | Compressa farmaceutica completamente rivestita per il rilascio controllato di principi attivi che presentano problemi di |
DE19707655A1 (de) | 1997-02-26 | 1998-08-27 | Hoechst Ag | Kombinationspräparat zur Anwendung bei Demenz |
CA2216215A1 (en) | 1997-04-05 | 1998-10-05 | Isa Odidi | Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
EP0988289A2 (en) * | 1997-06-05 | 2000-03-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds, their production and use |
TW446561B (en) * | 1997-06-30 | 2001-07-21 | Dev Center Biotechnology | Improved stabilization of prostaglandin drug |
FR2766708B1 (fr) | 1997-07-30 | 2000-05-05 | Galenix Dev | Composition contenant de l'hydroxypropylcellulose, de l'hydroxypropylmethylcellulose et/ou de l'ethylcellullose a titre d'agents desintegrants, et procede d'obtention |
US20040028735A1 (en) | 1997-11-14 | 2004-02-12 | Unchalee Kositprapa | Pharmaceutical formulation |
CO4980891A1 (es) | 1997-11-14 | 2000-11-27 | Sanofi Sa | Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer |
US20030092737A1 (en) | 1997-11-14 | 2003-05-15 | Pierre Maffrand Jean | Combination of active ingredients for the treatment of senile dementia of the Alzheimer type |
FR2772615B1 (fr) | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
US6251430B1 (en) | 1998-02-04 | 2001-06-26 | Guohua Zhang | Water insoluble polymer based sustained release formulation |
JP3987655B2 (ja) | 1998-03-03 | 2007-10-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗痴呆薬を含有した経皮適用製剤又は坐剤 |
US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
JP4533531B2 (ja) | 1998-04-03 | 2010-09-01 | ビーエム リサーチ エイ/エス | 制御放出組成物 |
US6262081B1 (en) | 1998-07-10 | 2001-07-17 | Dupont Pharmaceuticals Company | Composition for and method of treating neurological disorders |
UA73092C2 (uk) | 1998-07-17 | 2005-06-15 | Брістол-Майерс Сквібб Компані | Таблетка з ентеросолюбільним покриттям і спосіб її приготування |
US6638534B1 (en) | 1998-07-28 | 2003-10-28 | Tanabe Seiyaku Co., Ltd. | Preparation capable of releasing drug at target site in intestine |
KR100764520B1 (ko) | 1998-08-28 | 2007-10-09 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 고미 등을 경감한 의약조성물 |
DE19842753A1 (de) | 1998-09-18 | 2000-03-23 | Bayer Ag | Agitationsunabhängige pharmazeutische Retardzubereitungen und Verfahren zu ihrer Herstellung |
US6531152B1 (en) | 1998-09-30 | 2003-03-11 | Dexcel Pharma Technologies Ltd. | Immediate release gastrointestinal drug delivery system |
US20010055613A1 (en) | 1998-10-21 | 2001-12-27 | Beth A. Burnside | Oral pulsed dose drug delivery system |
WO2000024423A1 (fr) | 1998-10-26 | 2000-05-04 | Tanabe Seiyaku Co., Ltd. | Particules a liberation prolongee |
US6797283B1 (en) | 1998-12-23 | 2004-09-28 | Alza Corporation | Gastric retention dosage form having multiple layers |
DK1140105T3 (da) * | 1998-12-24 | 2004-02-23 | Janssen Pharmaceutica Nv | Galantaminpræparat med styret frigivelse |
US6659463B2 (en) | 1999-01-08 | 2003-12-09 | Thomas J. Mackey | Interconnecting miniature toy figurine bases with record tracking system |
DE19901040A1 (de) | 1999-01-14 | 2000-07-20 | Knoll Ag | Arzneiformen mit gesteuerter Freisetzung, enthaltend gut wasserlösliche Wirkstoffe |
ES2307482T3 (es) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | Dispersiones farmaceuticas solidas. |
ATE404178T1 (de) | 1999-02-10 | 2008-08-15 | Pfizer Prod Inc | Vorrichtung mit matrixgesteuerter wirkstofffreisetzung |
US6706283B1 (en) * | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
DK1086706T3 (da) * | 1999-03-31 | 2004-03-08 | Eisai Co Ltd | Stabiliserede sammensætninger indeholdende nootropiske lægemidler |
IL145661A0 (en) | 1999-03-31 | 2002-06-30 | Janssen Pharmaceutica Nv | Pregelatinized starch in a controlled release formulation |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US7919119B2 (en) | 1999-05-27 | 2011-04-05 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
US6632451B2 (en) | 1999-06-04 | 2003-10-14 | Dexcel Pharma Technologies Ltd. | Delayed total release two pulse gastrointestinal drug delivery system |
NZ517465A (en) | 1999-09-02 | 2003-10-31 | Nostrum Pharmaceuticals Inc | Controlled release pellet formulation |
GB9923045D0 (en) * | 1999-09-29 | 1999-12-01 | Novartis Ag | New oral formulations |
US20020107173A1 (en) * | 1999-11-04 | 2002-08-08 | Lawrence Friedhoff | Method of treating amyloid beta precursor disorders |
IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
US20030124176A1 (en) * | 1999-12-16 | 2003-07-03 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
BR0007360A (pt) | 1999-12-23 | 2001-08-14 | Johnson & Johnson | Composição de liberação controlada |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US20030144255A1 (en) | 2000-03-06 | 2003-07-31 | Bain Allen I | Compositions for prevention and treatment of dementia |
DE10013029A1 (de) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Mehrschichtige Arzneiform für die Colonfreigabe |
IN192159B (ko) | 2000-05-15 | 2004-02-28 | Ranbaxy Lab Ltd | |
DE10029201A1 (de) * | 2000-06-19 | 2001-12-20 | Basf Ag | Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
AU2001291526A1 (en) | 2000-09-22 | 2002-04-02 | Galephar M/F | Sustained release composition containing clarithromycin |
GB0025208D0 (en) | 2000-10-13 | 2000-11-29 | Euro Celtique Sa | Delayed release pharmaceutical formulations |
ES2220789T3 (es) | 2000-10-30 | 2004-12-16 | Lupin Limited | Composicion de cefuroxima axetilo de liberacion lenta que se desintegra rapidamente. |
CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
SE0004671D0 (sv) | 2000-12-15 | 2000-12-15 | Amarin Dev Ab | Pharmaceutical formulation |
US6287599B1 (en) | 2000-12-20 | 2001-09-11 | Shire Laboratories, Inc. | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles |
CA2350195C (en) | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
NZ528957A (en) | 2001-04-18 | 2005-05-27 | Nostrum Pharmaceuticals Inc | A novel coating for a sustained release pharmaceutical composition |
US20040022853A1 (en) | 2001-04-26 | 2004-02-05 | Control Delivery Systems, Inc. | Polymer-based, sustained release drug delivery system |
JP4310605B2 (ja) | 2001-05-25 | 2009-08-12 | 大塚製薬株式会社 | 医薬用組成物 |
JP2004534056A (ja) | 2001-06-08 | 2004-11-11 | エンドー ファーマシューティカルズ, インコーポレイティド | アクリルポリマーを使用する制御放出投薬形態、およびそれを作製するためのプロセス |
US6693769B2 (en) * | 2001-06-18 | 2004-02-17 | Hitachi Global Storage Technologies Netherlands B.V. | High data rate write head |
JP2004534812A (ja) * | 2001-06-22 | 2004-11-18 | ファイザー・プロダクツ・インク | 薬物および中性ポリマーの分散物の医薬組成物 |
JP3474870B2 (ja) * | 2001-08-08 | 2003-12-08 | 菱計装株式会社 | 昇降機 |
JP4848101B2 (ja) | 2001-08-17 | 2011-12-28 | 株式会社フジモト・コーポレーション | 徐放性マイクロペレット |
WO2003017981A1 (en) | 2001-08-29 | 2003-03-06 | Ranbaxy Laboratories Limited | Controlled release formulation of clarithromycin or tinidazol |
HUP0500791A2 (en) | 2001-08-29 | 2006-09-28 | Ranbaxy Lab Ltd | Controlled release formulation of clarithromycin or tinidazol |
HU226527B1 (hu) * | 2001-09-18 | 2009-03-30 | Nycomed Danmark Aps | Készítmények nátha kezelésére |
EP1429739A1 (en) | 2001-09-21 | 2004-06-23 | Egalet A/S | Polymer release system |
US20050191359A1 (en) | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
MXPA04002980A (es) | 2001-09-28 | 2005-06-20 | Johnson & Johnson | Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas. |
US20030118649A1 (en) | 2001-10-04 | 2003-06-26 | Jinming Gao | Drug delivery devices and methods |
US6592901B2 (en) | 2001-10-15 | 2003-07-15 | Hercules Incorporated | Highly compressible ethylcellulose for tableting |
AUPR839001A0 (en) | 2001-10-19 | 2001-11-15 | Eli Lilly And Company | Dosage form, device and methods of treatment |
SI1443917T1 (sl) | 2001-11-07 | 2006-06-30 | Synthon Bv | Tablete tamsulozina |
UA76256C2 (en) | 2001-11-21 | 2006-07-17 | Eisai Co Ltd | Composition containing acid-unstable physiologically active compound and process for its preparation |
US20050163846A1 (en) | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
WO2003053402A1 (en) | 2001-12-20 | 2003-07-03 | Pharmacia Corporation | Zero-order sustained released dosage forms and method of making the same |
KR100540035B1 (ko) | 2002-02-01 | 2005-12-29 | 주식회사 태평양 | 다단계 경구 약물 방출 제어 시스템 |
CA2475385A1 (en) | 2002-02-07 | 2003-08-14 | Eisai Co., Ltd. | Hair growth promoting agent, percutaneously applied preparation, and hair growth promoting method |
HRP20020124A2 (en) | 2002-02-11 | 2003-10-31 | Pliva D D | Sustained/controlled release solid formulation as a novel drug delivery system with reduced risk of dose dumping |
GB0203296D0 (en) | 2002-02-12 | 2002-03-27 | Glaxo Group Ltd | Novel composition |
JP4355925B2 (ja) | 2002-02-21 | 2009-11-04 | 大塚製薬株式会社 | 徐放製剤及びその製造方法 |
DE10208344A1 (de) | 2002-02-27 | 2003-09-04 | Roehm Gmbh | Schmelzextrusion von Wirkstoffsalzen |
GB0204772D0 (en) | 2002-02-28 | 2002-04-17 | Phoqus Ltd | Pharmaceutical dosage forms |
ITMI20020515A1 (it) | 2002-03-12 | 2003-09-12 | Jagotec Ag | Sistema per il rilasco controllato di uno o piu' principi attivi |
JP5105684B2 (ja) | 2002-03-15 | 2012-12-26 | 大塚製薬株式会社 | 持続性医薬製剤 |
AU2003225102A1 (en) | 2002-04-23 | 2003-11-10 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
FR2838647B1 (fr) | 2002-04-23 | 2006-02-17 | Particules enrobees a liberation prolongee, leur procede de preparation et comprimes les contenant | |
WO2003096874A2 (en) | 2002-05-15 | 2003-11-27 | Sun Pharmaceutical Industries Limited | Coated sustained release tablets of a hygroscopic compound for once-a-day therapy |
DE10224170A1 (de) | 2002-05-31 | 2003-12-11 | Desitin Arzneimittel Gmbh | Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung |
CN1668284A (zh) | 2002-06-07 | 2005-09-14 | 兰贝克赛实验室有限公司 | 加巴喷丁的缓释口服剂型 |
SI21223A (sl) | 2002-06-19 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Farmacevtska formulacija s stabiliziranim amorfnim donepezilijevim kloridom |
IL150509A (en) | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical preparations containing donafazil hydrochloride |
WO2004017938A2 (en) | 2002-08-23 | 2004-03-04 | Ranbaxy Laboratories Limited | Nitrofurantoin controlled release dosage form |
US20040052844A1 (en) | 2002-09-16 | 2004-03-18 | Fang-Hsiung Hsiao | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins |
US20050048119A1 (en) | 2002-09-20 | 2005-03-03 | Avinash Nangia | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
CN100339070C (zh) | 2002-10-24 | 2007-09-26 | 莫茨药物股份两合公司 | 包含1-氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物 |
CA2511431A1 (en) | 2002-10-24 | 2004-05-06 | Immupharm A/S | Pharmaceutical compositions comprising flavonoids and menthol |
WO2004041195A2 (en) | 2002-10-31 | 2004-05-21 | Supergen, Inc. | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
US7988993B2 (en) | 2002-12-09 | 2011-08-02 | Andrx Pharmaceuticals, Inc. | Oral controlled release dosage form |
WO2004058309A1 (en) * | 2002-12-23 | 2004-07-15 | Human Genome Sciences, Inc. | Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof |
CA2514879C (en) | 2003-01-03 | 2014-09-16 | Shire Laboratories Inc. | Two or more enteric materials to regulate drug release |
AU2004207523A1 (en) | 2003-01-24 | 2004-08-12 | Control Delivery Systems, Inc. | Controlled release of highly soluble agents |
US20040258752A1 (en) | 2003-01-31 | 2004-12-23 | Paruthi Manoj Kumar | Taste masking pharmaceutical composition and process for its preparation |
US20040185097A1 (en) | 2003-01-31 | 2004-09-23 | Glenmark Pharmaceuticals Ltd. | Controlled release modifying complex and pharmaceutical compositions thereof |
IL154370A0 (en) | 2003-02-10 | 2003-09-17 | Chemagis Ltd | Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same |
US7439365B2 (en) | 2003-11-17 | 2008-10-21 | Usv, Ltd. | Pharmaceutical salt of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine (Donepezil) |
AR043467A1 (es) | 2003-03-05 | 2005-07-27 | Osmotica Argentina S A | Combinacion de drogas para la disfuncion motora en la enfermedad de parkinson |
JP4933033B2 (ja) * | 2003-03-17 | 2012-05-16 | 武田薬品工業株式会社 | 放出制御組成物 |
CA2519208A1 (en) * | 2003-03-17 | 2004-09-30 | Takeda Pharmaceutical Company Limited | Controlled release composition |
US20060210633A1 (en) | 2003-04-03 | 2006-09-21 | Sun Pharmaceutical Industries Limited | Programmed drug delivery system |
MXPA05010636A (es) | 2003-04-04 | 2005-12-12 | Pharmacia Corp | Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada. |
US20040208928A1 (en) | 2003-04-15 | 2004-10-21 | Animal Technology Institute Taiwan | Method for preparing an orally administrable formulation for controlled release |
US20040265375A1 (en) | 2003-04-16 | 2004-12-30 | Platteeuw Johannes J. | Orally disintegrating tablets |
US20040208932A1 (en) | 2003-04-17 | 2004-10-21 | Ramachandran Thembalath | Stabilized paroxetine hydrochloride formulation |
WO2004103342A2 (en) | 2003-05-16 | 2004-12-02 | Alkermes Controlled Therapeutics, Inc. | Injectable sustained release compositions |
JP2004339162A (ja) | 2003-05-16 | 2004-12-02 | Shin Etsu Chem Co Ltd | 難溶性薬物を含む医薬用固形製剤とその製造方法 |
EP2529730A1 (en) | 2003-06-16 | 2012-12-05 | ANDRX Pharmaceuticals LLC. | Oral sustained-release composition |
KR20060033727A (ko) | 2003-06-16 | 2006-04-19 | 알러간, 인코포레이티드 | 메만틴 경구 투여 제형 |
RU2375048C2 (ru) | 2003-07-17 | 2009-12-10 | Д-Р Редди'С Лабораторис Инк. | Фармацевтическая композиция с набухающим покрытием |
US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
US20050025829A1 (en) | 2003-07-29 | 2005-02-03 | Kim Cherng-Ju | Controlled drug release tablets |
WO2005016306A2 (en) | 2003-08-06 | 2005-02-24 | Alza Corporation | Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation |
EP1658048A2 (en) | 2003-08-22 | 2006-05-24 | ALZA Corporation | Stepwise delivery of topiramate over prolonged period of time |
NZ545921A (en) | 2003-09-19 | 2009-09-25 | Penwest Pharmaceuticals Co | Delayed released dosage forms |
MXPA06003453A (es) | 2003-09-26 | 2006-08-31 | Johnson & Johnson | Barra de empuje oros para el suministro controlado de agentes activos. |
EP1523979A1 (en) | 2003-10-13 | 2005-04-20 | Wyeth | Extended release pharmaceutical dosage form |
US20050084531A1 (en) | 2003-10-16 | 2005-04-21 | Jatin Desai | Tablet with aqueous-based sustained release coating |
US20050129751A1 (en) | 2003-12-16 | 2005-06-16 | Rothenberg Barry E. | Drug delivery compositions and methods |
US20050129759A1 (en) | 2003-12-16 | 2005-06-16 | Milan Sojka | Sustained release compositions and controlled delivery method |
WO2005063206A1 (en) | 2003-12-23 | 2005-07-14 | Alza Corporation | Methods and dosage forms for increasing solubility of drug compositions for controlled delivery |
US20050175696A1 (en) | 2003-12-29 | 2005-08-11 | David Edgren | Drug granule coatings that impart smear resistance during mechanical compression |
CA2552221A1 (en) | 2003-12-31 | 2005-07-21 | Actavis Group Hf | Donepezil formulations |
US20050163843A1 (en) | 2003-12-31 | 2005-07-28 | Garth Boehm | Alprazolam formulations |
US20050191349A1 (en) * | 2003-12-31 | 2005-09-01 | Garth Boehm | Galantamine formulations |
JP2007519724A (ja) | 2004-01-26 | 2007-07-19 | シヴィダ・インコーポレイテッド | 核酸を基剤とする治療剤の制御送達および持続的送達 |
US7670624B2 (en) | 2004-01-29 | 2010-03-02 | Astella Pharma Inc. | Gastrointestinal-specific multiple drug release system |
US20050181044A1 (en) | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements, green coffee extract |
US20050181047A1 (en) | 2004-02-18 | 2005-08-18 | Jaime Romero | Compositions and methods for timed release of water-soluble nutritional supplements |
US20050186275A1 (en) | 2004-02-23 | 2005-08-25 | Standard Chem. & Pharm. Co. Ltd. | Sustained release tamsulosin formulations |
TW200534879A (en) | 2004-03-25 | 2005-11-01 | Bristol Myers Squibb Co | Coated tablet formulation and method |
NZ549838A (en) | 2004-03-26 | 2010-04-30 | Eisai R&D Man Co Ltd | Coated controlled-release preparation containing a gastric acid secretion inhibitor |
US20050220875A1 (en) | 2004-03-31 | 2005-10-06 | Agency For Science, Technology And Research | Sustained-release tablet formulation |
US20050220877A1 (en) | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
US8535716B2 (en) | 2004-04-01 | 2013-09-17 | Tsrl, Inc. | Methods and composition of extended delivery of water insoluble drugs |
US20050226929A1 (en) | 2004-04-12 | 2005-10-13 | Jianbo Xie | Controlled release opioid analgesic formulation |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
WO2006063025A1 (en) * | 2004-12-07 | 2006-06-15 | Nektar Therapeutics | Stable non-crystalline formulation comprising donepezil |
NZ555693A (en) | 2004-12-27 | 2010-10-29 | Eisai R&D Man Co Ltd | Matrix type sustained-release preparation containing donepezil |
US20060280789A1 (en) | 2004-12-27 | 2006-12-14 | Eisai Research Institute | Sustained release formulations |
US20060246003A1 (en) | 2004-12-27 | 2006-11-02 | Eisai Co. Ltd. | Composition containing anti-dementia drug |
US20090208579A1 (en) | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
JP5666087B2 (ja) | 2005-04-06 | 2015-02-12 | アダマス・ファーマシューティカルズ・インコーポレーテッド | Cns関連疾患の治療のための方法及び組成物 |
CA2604617C (en) | 2005-04-28 | 2014-06-17 | Eisai R&D Management Co., Ltd. | Composition containing anti-dementia drug |
CN1709229A (zh) | 2005-06-10 | 2005-12-21 | 北京阜康仁生物制药科技有限公司 | 盐酸美金刚口腔崩解片及其制备方法 |
-
2005
- 2005-12-27 NZ NZ555693A patent/NZ555693A/en not_active IP Right Cessation
- 2005-12-27 US US11/793,722 patent/US8481565B2/en active Active
- 2005-12-27 JP JP2007529288A patent/JP2008525313A/ja not_active Withdrawn
- 2005-12-27 EP EP05824466.6A patent/EP1830886B1/en active Active
- 2005-12-27 AU AU2005320547A patent/AU2005320547B2/en not_active Ceased
- 2005-12-27 MX MX2007007836A patent/MX2007007836A/es active IP Right Grant
- 2005-12-27 BR BRPI0518396-0A patent/BRPI0518396A2/pt not_active Application Discontinuation
- 2005-12-27 CA CA2592605A patent/CA2592605C/en not_active Expired - Fee Related
- 2005-12-27 RU RU2007128767/15A patent/RU2401125C2/ru not_active IP Right Cessation
- 2005-12-27 WO PCT/JP2005/024254 patent/WO2006070930A1/en active Application Filing
- 2005-12-27 KR KR1020077014535A patent/KR100866720B1/ko active IP Right Grant
-
2007
- 2007-06-04 IL IL183650A patent/IL183650A/en not_active IP Right Cessation
- 2007-07-05 NO NO20073482A patent/NO20073482L/no not_active Application Discontinuation
-
2008
- 2008-02-05 HK HK08101338.1A patent/HK1112399A1/zh unknown
-
2010
- 2010-02-25 US US12/712,959 patent/US8507527B2/en active Active
-
2012
- 2012-04-24 JP JP2012098985A patent/JP5514249B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11106353A (ja) * | 1997-10-01 | 1999-04-20 | Eisai Co Ltd | 光安定化組成物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180036579A (ko) | 2016-09-30 | 2018-04-09 | 주식회사 바이오파마티스 | 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법 |
WO2020130287A1 (ko) | 2018-12-21 | 2020-06-25 | 동아에스티 주식회사 | 안정화된 도네페질 함유 경피 흡수제제 |
Also Published As
Publication number | Publication date |
---|---|
US8481565B2 (en) | 2013-07-09 |
RU2401125C2 (ru) | 2010-10-10 |
NO20073482L (no) | 2007-09-27 |
US20100152164A1 (en) | 2010-06-17 |
EP1830886A4 (en) | 2012-10-10 |
AU2005320547A1 (en) | 2006-07-06 |
MX2007007836A (es) | 2007-08-20 |
EP1830886A1 (en) | 2007-09-12 |
JP2012144568A (ja) | 2012-08-02 |
IL183650A0 (en) | 2007-09-20 |
AU2005320547B2 (en) | 2009-02-05 |
CA2592605A1 (en) | 2006-07-06 |
EP1830886B1 (en) | 2016-04-13 |
NZ555693A (en) | 2010-10-29 |
HK1112399A1 (zh) | 2008-09-05 |
WO2006070930A1 (en) | 2006-07-06 |
BRPI0518396A2 (pt) | 2008-11-18 |
KR20070086667A (ko) | 2007-08-27 |
RU2007128767A (ru) | 2009-02-10 |
IL183650A (en) | 2013-12-31 |
JP5514249B2 (ja) | 2014-06-04 |
CA2592605C (en) | 2010-12-07 |
US8507527B2 (en) | 2013-08-13 |
US20080213368A1 (en) | 2008-09-04 |
JP2008525313A (ja) | 2008-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100866720B1 (ko) | 항치매 약물의 안정화 방법 | |
US6187340B1 (en) | Stabilized pharmaceutical preparation | |
KR101647842B1 (ko) | 저장 안정성이 개선된 의약 조성물 | |
US20060280789A1 (en) | Sustained release formulations | |
US20090208579A1 (en) | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same | |
US20140099366A1 (en) | Composition Containing Two Anti-Dementia Drugs | |
KR20160101720A (ko) | Azd9291을 포함하는 제약 조성물 | |
US20070129402A1 (en) | Sustained release formulations | |
JP6288158B2 (ja) | 品質が向上した経口製剤 | |
US20060159753A1 (en) | Matrix type sustained-release preparation containing basic drug or salt thereof | |
CN101090737B (zh) | 稳定抗痴呆药物的方法 | |
US20080268049A1 (en) | Stable Solid Dosage Forms of Amlodipine and Benazepril | |
JP4730985B2 (ja) | 安定化された医薬製剤 | |
TW202200123A (zh) | 一種複合物的藥物組合物及其製備方法 | |
KR102206104B1 (ko) | 실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형 | |
US20200078463A1 (en) | Composition having improved water solubility and bioavailability | |
KR101794573B1 (ko) | 콜린알포세레이트를 포함하는 속방출형 고형제제 및 이의 제조방법 | |
CA2893480C (en) | Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide | |
EP3236950A1 (en) | Pharmaceutical composition comprising candesartan or pharmaceutically acceptable salts or esters thereof and amlodipine or pharmaceutically acceptable salts thereof | |
KR20120122558A (ko) | 도네페질 또는 이의 약학적으로 허용되는 염을 포함하는 용출 안정성이 개선된 서방형 약학 조성물 및 이의 제조방법 | |
NZ625506B2 (en) | Compositions For Treatment of Heart Failure in Dogs. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121019 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20131018 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20141017 Year of fee payment: 7 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20151016 Year of fee payment: 8 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20150408 Effective date: 20151028 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20161021 Year of fee payment: 9 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2016100003235; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20161018 Effective date: 20170424 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100001106; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170411 Effective date: 20170830 |
|
FPAY | Annual fee payment |
Payment date: 20171020 Year of fee payment: 10 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20181023 Year of fee payment: 11 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100004074; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20171229 Effective date: 20190507 |